Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteomic analysis of a CFF1 deletion mutant under rapamycin treatment

ABSTRACT: Yeast harbouring a CFF1 deletion as well as wild-type S. cerevisiae were treated with either the drug rapamycin or a control for 30 minutes. Protein extracts were generated and the resulting peptides were subjected to tryptic digestion and bottom up, data independent proteome analysis.

INSTRUMENT(S): Q Exactive HF-X

ORGANISM(S): Saccharomyces Cerevisiae (ncbitaxon:4932)

SUBMITTER: Duncan Holbrook-Smith

PROVIDER: MSV000089940 | MassIVE | Thu Jul 21 12:51:00 BST 2022

REPOSITORIES: MassIVE

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Proteomic analysis of yeast mutants treated with rapamycin

Project description:7 S. cerevisiae loss-of-function mutants were treated with either the drug rapamycin or a control for 30 minutes. Protein extracts were generated and the resulting peptides were subjected to tryptic digestion and bottom up, data independent proteome analysis.

2022-07-21 | MSV000089935 | MassIVE

Dynamic mRNA gene expression following a rapamycin treatment

Project description:Dynamic mRNA gene expression from the wildtype YSBN6 during a rapamycin treatment (rapamycin-induced downshift). Rapamycin was added to yeast cells growing exponentially on glutamine as sole nitrogen source. A sample was taken at steady-state 10 minutes before , and then 3, 7, 10, 14, 24, 56 and 120 minutes after rapamycin treatment. Biological triplicate gene expression was measured for samples -10, 7 and 24 minutes after shift, for a total of 14 chips. Changes were generally evaluated relative to the steady-state point (-10 minutes). Biological variability can be assessed from the replicates time points. Other dynamic omics data are associated with this dataset. Consult the publication for more details.

2015-04-07 | E-GEOD-54851 | biostudies-arrayexpress

Transcription profiling by array of yeast ARO80, DAT1 and RTG3 deletion mutants after rapamycin perturbation

Project description:We profiled the expression levels of three single deletion mutants (ARO80, DAT1, RTG3) of the the wild type strain BY4742 50 minutes after rapamycin perturbation. Our goal is to validate regulatory networks inferred from microarray data E-MTAB-412.

2011-09-30 | E-MTAB-446 | biostudies-arrayexpress

Transcription profiling of rapamycin treated wild type and ume1-deletion yeast

Project description:Rapamycin treatment of wild type and ume1-delta yeast S. cerevisiae strain.

2008-09-04 | E-MEXP-1782 | biostudies-arrayexpress

Pol III transcription machinery occupancy monitoring upon rapamycin treatment

Project description:Effects of Maf1 deletion on the promoter occupancy during transcriptional repression by rapamycin Keywords: ChIP-Chip time course

2006-04-30 | GSE3468 | GEO

Yeast m6A methylated mRNAs are enriched on translating ribosomes during meiosis, and under Rapamycin treatment

Project description:Interest in mRNA methylation has exploded in recent years. The sudden interest in a 40 year old discovery was due in part to the recent finding of FTO?s (Fat Mass Obesity) N6-methyl-adenosine (m6A) deaminase activity, thus suggested a link between obesity-associated diseases and the presence of m6A in mRNA. Another catalyst of the sudden rise in mRNA methylation research was the release of mRNA methylomes for human, mouse and Saccharomyces cerevisiae. However, the molecular function, or functions of this mRNA ?epimark? remain to be discovered. There is supportive evidence that m6A could be a mark for mRNA degradation due to its binding to YTH domain proteins, and consequently being chaperoned to P bodies. Nonetheless, only a subpopulation of the methylome was found binding to YTHDF2 in HeLa cells. The model organism Saccharomyces cerevisiae, has only one YTH domain protein (Pho92, Mrb1), which targets PHO4 transcripts for degradation under phosphate starvation. However, mRNA methylation is only found under meiosis inducing conditions, and PHO4 transcripts are apparently non-methylated. In this paper we set out to investigate if m6A could function alternatively to being a degradation mark in S. cerevisiae, we also sought to test whether it can be induced under non-standard sporulation conditions. We find associations between the presence of m6A and message translatability. We also find m6A induction following prolonged rapamycin treatment.

2015-08-12 | GSE68435 | GEO

Transcription profiling of yeast treated with rapamycin in a 7-part time series

Project description:This experiment was a 7-part time series (or, 2x7 factorial design) examining the effect of rapamycin on gene expression in Saccharomyces cerevisiae. Treated and untreated cultures were compared at 0, 20, 40, 60, 120, 240, and 360 minutes. In the paper, expression ratios (mRNA) at each time point were compared to equivalent ratios (protein) from shotgun proteomics NSAF data. High-expressing mRNA ratios were also clustered and GO-characterized.

2010-02-05 | E-TABM-639 | biostudies-arrayexpress

Yeast m6A methylated mRNAs are enriched on translating ribosomes during meiosis, and under Rapamycin treatment

2015-08-12 | E-GEOD-68435 | biostudies-arrayexpress

ChIP-chip by array of yeast wild type and rrd1 deletion strains treated with rapamycin

Project description:Determination of RNAPII, Rrd1-Myc, RNAPII-Ser2-P, RNAPII-Ser5-P abundance between wildtype and rrd1 deletion strains under rapamycin or control treatments.Rapamycin is an anticancer agent and immunosuppressant that acts by inhibiting the TOR signaling pathway. In yeast, rapamycin mediates a profound transcriptional response for which the RRD1 gene is required. To further investigate this connection, we performed genome-wide association studies of RNA polymerase II (RNAPII) and Rrd1 in response to rapamycin and demonstrate that Rrd1 colocalizes with RNAPII on actively transcribed genes and both are recruited to rapamycin responsive genes. Strikingly, when Rrd1 is lacking, RNAPII remains inappropriately associated to ribosomal genes and fails to be recruited to rapamycin responsive genes. This occurs independently of TATA box binding protein recruitment. Furthermore, Rrd1 modulates the phosphorylation status of RNAPII CTD and additional evidence suggests that Rrd1 is involved in various transcriptional stress responses. We propose that Rrd1 is a novel transcription elongation factor that fine-tunes the transcriptional stress response of RNAPII.

2010-11-30 | E-MEXP-2763 | biostudies-arrayexpress

Dynamic mRNA gene expression following a rapamycin treatment

2015-04-07 | GSE54851 | GEO